Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -170.49% is 58% below its 5-year average of -108.04%, around the middle of its 5-year range (-388.26%–-23.14%).
As of the fiscal period ended Tuesday, June 30, 2026. 11.84% above its 12-month average of -193.39%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -170.49%.
RETURN ON EQUITY (ROE)
-170.49%
RETURN ON EQUITY (ROE) AVG TTM
-193.39%
RETURN ON EQUITY (ROE) AVG 3Y
-147.76%
RETURN ON EQUITY (ROE) AVG 5Y
-108.04%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+11.84%
CURRENT VS 3Y AVG
-15.38%
CURRENT VS 5Y AVG
-57.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.20%
median of 733 covered companies
CURRENT VS SECTOR MEDIAN
-313.80%
vs the sector median at left
Neuronetics, Inc.
Market Cap
$155.53M
Return on Equity (ROE)
-170.49%
TTM Avg
-193.39%
3Y Avg
-147.76%
5Y Avg
-108.04%
Market Cap
$154.79M
Return on Equity (ROE)
-266.86%
TTM Avg
156.76%
3Y Avg
98.17%
5Y Avg
-694.29%
Market Cap
$154.72M
Return on Equity (ROE)
N/A
TTM Avg
13.51%
3Y Avg
15.58%
5Y Avg
15.05%
Market Cap
$157.57M
Return on Equity (ROE)
-14.07%
TTM Avg
-16.23%
3Y Avg
-27.66%
5Y Avg
-19.01%
Market Cap
$158.58M
Return on Equity (ROE)
-60.19%
TTM Avg
-68.34%
3Y Avg
-61.91%
5Y Avg
-47.91%
Market Cap
$159.91M
Return on Equity (ROE)
-215.26%
TTM Avg
-150.35%
3Y Avg
8.65%
5Y Avg
-35.35%
Market Cap
$160.27M
Return on Equity (ROE)
N/A
TTM Avg
101.44%
3Y Avg
117.16%
5Y Avg
-25.56%
Market Cap
$149.36M
Return on Equity (ROE)
-59.40%
TTM Avg
-255.06%
3Y Avg
-160.44%
5Y Avg
-112.56%
Market Cap
$149.28M
Return on Equity (ROE)
-155.34%
TTM Avg
-168.75%
3Y Avg
-117.97%
5Y Avg
-104.46%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuronetics, Inc. (STIM) | $155.53M | -170.49% | -193.39% | -147.76% | -108.04% |
| LifeMD, Inc. (LFMDP)vs › | $154.79M | -266.86% | 156.76% | 98.17% | -694.29% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $154.72M | N/A | 13.51% | 15.58% | 15.05% |
| Inogen, Inc. (INGN)vs › | $157.57M | -14.07% | -16.23% | -27.66% | -19.01% |
| PepGen Inc. (PEPG)vs › | $158.58M | -60.19% | -68.34% | -61.91% | -47.91% |
| Coherus Oncology, Inc. (CHRS)vs › | $159.91M | -215.26% | -150.35% | 8.65% | -35.35% |
| Minerva Neurosciences, Inc. (NERV)vs › | $160.27M | N/A | 101.44% | 117.16% | -25.56% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | -59.40% | -255.06% | -160.44% | -112.56% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $149.28M | -155.34% | -168.75% | -117.97% | -104.46% |
| Korsana Biosciences, Inc. (KRSA)vs › | $149.01M | -131.85% | -36.69% | -135.43% | -129.92% |
ROE
-170.5%
ROA
-23.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -170.49% |
| 2026-03-31 | -279.78% |
| 2025-12-31 | -174.27% |
| 2025-09-30 | -162.68% |
| 2025-06-30 | -179.75% |
| 2025-03-31 | -136.83% |
| 2024-12-31 | -157.76% |
| 2024-09-30 | -388.26% |
| 2024-06-30 | -167.51% |
| 2024-03-31 | -99.59% |
| 2023-12-31 | -88.30% |
| 2023-09-30 | -87.25% |
| 2023-06-30 | -68.87% |
| 2023-03-31 | -76.20% |
| 2022-12-31 | -65.12% |
| 2022-09-30 | -57.95% |
| 2022-06-30 | -54.14% |
| 2022-03-31 | -44.58% |
| 2021-12-31 | -36.62% |
| 2021-09-30 | -29.88% |
| 2021-06-30 | -23.14% |
| 2021-03-31 | -22.28% |
| 2020-12-31 | -107.69% |
| 2020-09-30 | -114.09% |
| 2020-06-30 | -118.20% |
| 2020-03-31 | -93.47% |
| 2019-12-31 | -60.70% |
| 2019-09-30 | -50.86% |
| 2019-06-30 | -43.01% |
| 2019-03-31 | -39.94% |
| 2018-12-31 | -33.92% |
| 2018-09-30 | -29.97% |
